GSA Capital Partners LLP Invests $46,000 in Bionano Genomics, Inc. (NASDAQ:BNGO)

GSA Capital Partners LLP acquired a new stake in Bionano Genomics, Inc. (NASDAQ:BNGO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 100,414 shares of the company’s stock, valued at approximately $46,000. GSA Capital Partners LLP owned approximately 0.12% of Bionano Genomics at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of BNGO. Virtu Financial LLC purchased a new position in Bionano Genomics during the 1st quarter valued at about $36,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after acquiring an additional 38,900 shares during the last quarter. Carret Asset Management LLC increased its position in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after purchasing an additional 40,055 shares in the last quarter. Cetera Advisors LLC acquired a new position in Bionano Genomics in the 1st quarter valued at about $163,000. Finally, Armistice Capital LLC purchased a new position in Bionano Genomics in the 2nd quarter valued at about $1,138,000. 11.35% of the stock is currently owned by hedge funds and other institutional investors.

Bionano Genomics Trading Up 12.2 %

NASDAQ BNGO opened at $0.25 on Tuesday. The company has a 50-day moving average of $0.34 and a 200-day moving average of $0.57. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99. Bionano Genomics, Inc. has a 12 month low of $0.20 and a 12 month high of $2.27. The company has a market cap of $25.64 million, a P/E ratio of -0.11 and a beta of 2.37.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. BTIG Research downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 10th. Scotiabank reaffirmed a “sector perform” rating and issued a $1.00 target price (down from $6.00) on shares of Bionano Genomics in a research note on Wednesday, August 28th. Finally, LADENBURG THALM/SH SH lowered Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.